Justification for Other than Full and Open Competition-FAR Part 13 Acq under SAT_ADAM_Redacted.pdf

This document is a Justification for Other than Full and Open Competition under FAR Part 13 Acquisitions below the Simplified Acquisition Threshold (SAT). It details a sole source award for the annual drop shipment of NanoEntek America ADAM (Advanced Detection and Accurate Measurement) residual White Blood Cell (rWBC) Kits to the U.S. Naval Hospital Okinawa, Japan. The Defense Health Agency awarded a firm-fixed price contract to NanoEntek America, Inc. on August 14, 2024 for a base plus four option years, with a total contract value of $78,052.80. The requirement was not awarded competitively due to exclusive licensing of the supplies. The contract provides for the annual delivery of the FDA-approved ADAM rWBC Kits to the U.S. Naval Hospital Okinawa.